Comparative Pharmacology
Head-to-head clinical analysis: ETHOSUXIMIDE versus LAMICTAL CD.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETHOSUXIMIDE versus LAMICTAL CD.
ETHOSUXIMIDE vs LAMICTAL CD
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ethosuximide reduces the frequency of spike-and-wave discharges in absence seizures by blocking T-type calcium channels in thalamic neurons, thereby stabilizing neuronal membrane and preventing rhythmic burst firing.
Lamotrigine is a phenyltriazine anticonvulsant that stabilizes neuronal membranes by blocking voltage-sensitive sodium channels and inhibiting the presynaptic release of excitatory neurotransmitters such as glutamate and aspartate.
Adults: 500 mg orally twice daily initially, increase by 250 mg every 4-7 days as needed; maintenance dose 1-2 g/day divided into 2-4 doses. Maximum 1.5 g/dose or 3 g/day.
Lamotrigine extended-release (LAMICTAL CD) for epilepsy: initial 50 mg orally once daily for 2 weeks, then 100 mg once daily for 2 weeks, then 200 mg once daily for 2 weeks, then 300 mg once daily for 2 weeks, then 400 mg once daily thereafter. For bipolar disorder: initial 25 mg once daily for 2 weeks, then 50 mg once daily for 2 weeks, then 100 mg once daily for 2 weeks, then 200 mg once daily thereafter.
None Documented
None Documented
Clinical Note
moderateEthosuximide + Sulfisoxazole
"The metabolism of Sulfisoxazole can be decreased when combined with Ethosuximide."
Clinical Note
moderateEthosuximide + Erythromycin
"The metabolism of Erythromycin can be decreased when combined with Ethosuximide."
Clinical Note
moderateEthosuximide + Cyclosporine
"The metabolism of Cyclosporine can be decreased when combined with Ethosuximide."
Clinical Note
moderateEthosuximide + Fluconazole
Terminal elimination half-life is approximately 60 hours (range 40–60 hours) in adults; children may have shorter half-life (~30–40 hours). Long half-life allows once- or twice-daily dosing.
Terminal elimination half-life in adults is approximately 25.4 hours (range 14-50 hours) in healthy volunteers; reduced to 14.5 hours (range 12-20) with enzyme-inducing antiepileptics (e.g., carbamazepine, phenytoin), increased to 59 hours (range 30-90) with valproate, and prolonged in renal impairment.
Primarily renal excretion; ~20% as unchanged ethosuximide and ~50% as conjugated metabolite (glucuronide plus minor hydroxymetabolites). Less than 5% eliminated via feces.
Lamotrigine is primarily eliminated by hepatic metabolism, with approximately 94% of the dose excreted in urine as glucuronide conjugates (10% as unchanged drug) and 2% in feces.
Category C
Category C
Anticonvulsant
Anticonvulsant
"The metabolism of Fluconazole can be decreased when combined with Ethosuximide."